Search results
Showing 1 to 15 of 52 results for sight loss
Highly specialised technologies evaluation committee members
Highly specialised technologies evaluation committee members
Evidence-based recommendations on ranibizumab (Lucentis) for treating diabetic macular oedema in adults.
View recommendations for TA274Show all sections
Evidence-based recommendations on nerve graft for corneal denervation. This involves attaching a healthy nerve to the damaged cornea to improve healing.
View recommendations for IPG729Show all sections
NICE recommends faricimab as treatment option for adults with wet age-related macular degeneration or diabetic macular oedema
A quick guide to promoting positive mental wellbeing for older people
Atidarsagene autotemcel for treating metachromatic leukodystrophy (HST18)
Evidence-based recommendations on atidarsagene autotemcel (Libmeldy) for treating metachromatic leukodystrophy in children.
Children with a rare, fatal, genetic disorder will be able to benefit from a new one-off treatment under new NICE guidance.
Selective laser therapy recommended to treat glaucoma and ocular hypertension
People newly diagnosed with glaucoma and ocular hypertension (OHT) should initially be offered selective laser therapy (SLT) treatment rather than eye drops, according to an updated NICE guideline published today (Wednesday, 26 January).
This guideline covers diagnosing and managing glaucoma in people aged 18 and over. It includes recommendations on testing and referral (case-finding) for chronic open-angle glaucoma and ocular hypertension and on effective diagnosis, treatment and reassessment to stop these conditions progressing.
NICE has developed a medtech innovation briefing (MIB) on AI technologies for detecting diabetic retinopathy .
Cerliponase alfa for treating neuronal ceroid lipofuscinosis type 2 (HST12)
Evidence-based recommendations on cerliponase alfa (Brineura) for treating neuronal ceroid lipofuscinosis type 2 in children.
Attention deficit hyperactivity disorder: diagnosis and management (NG87)
This guideline covers recognising, diagnosing and managing attention deficit hyperactivity disorder (ADHD) in children, young people and adults. It aims to improve recognition and diagnosis, as well as the quality of care and support for people with ADHD.
Fluocinolone acetonide intravitreal implant for treating recurrent non-infectious uveitis (TA590)
Evidence-based recommendations on fluocinolone acetonide intravitreal implant (Iluvien) for treating recurrent non-infectious uveitis in adults.
This quality standard covers preventing dementia, and assessment, management and health and social care support for people with dementia. It describes high-quality care in priority areas for improvement.
View quality statements for QS184Show all sections
Sections for QS184
- Quality statements
- Quality statement 1: Raising awareness – health promotion interventions
- Quality statement 2: Diagnosis
- Quality statement 3: Advance care planning
- Quality statement 4: Coordinating care
- Quality statement 5: Activities to promote wellbeing
- Quality statement 6: Managing distress
- Quality statement 7: Supporting carers
This quality standard covers the diagnosis and management of cataracts, glaucoma and age-related macular degeneration (AMD) and the prevention of sight loss. It describes high-quality care in priority areas for improvement.
View quality statements for QS180Show all sections
Sections for QS180
- Quality statements
- Quality statement 1: Referral – chronic open angle glaucoma and related conditions
- Quality statement 2: Referral for cataract surgery
- Quality statement 3: Treatment – late age-related macular degeneration (wet active)
- Quality statement 4: Monitoring late age-related macular degeneration (wet active)
- Quality statement 5: Reassessment – chronic open angle glaucoma or related conditions
- Quality statement 6: Certificate of vision impairment
- Update information